Medera Gains DMC Clearance to Advance SRD-002 HFpEF Gene Therapy Into Randomized Phase

An independent Data Monitoring Committee's unqualified recommendation to continue Medera Inc.'s MUSIC-HFpEF trial without protocol modification signals that the AAV1/SERCA2a program's safety profile is holding across both dose cohorts, a prerequisite the company needed before opening FDA discussions on the next randomized development stage.

The DMC completed its scheduled review of accumulated safety and clinical data from all ten treated patients across two dose cohorts: Cohort A at 3.0 × 10¹³ vg and Cohort B at 4.5 × 10¹³ vg. No gene therapy-related serious adverse events have been reported. The committee's assessment covered adverse events, laboratory assessments, hepatic function, immune monitoring, and cardiovascular safety endpoints, the standard surveillance package regulators expect for an AAV vector program at this stage.

For QA and regulatory leads tracking gene therapy manufacturing strategy, the program's delivery architecture carries direct GMP implications. SRD-002 is administered via Medera's proprietary targeted intracoronary platform, a catheter-based outpatient procedure designed to achieve localized cardiac gene transfer while substantially reducing systemic vector exposure and total vector dose requirements relative to conventional intravenous administration. Lower dose requirements compress the per-batch yield burden, but the intracoronary route introduces its own sterility assurance and fill-finish controls that diverge from standard parenteral GMP frameworks under 21 CFR Part 211 and ICH Q10 quality system expectations.

Clinical data presented at the American Heart Association Scientific Sessions 2025 showed Cohort A patients, all of whom have completed 12-month follow-up, with improvements in NYHA functional class, KCCQ scores, and hemodynamic parameters including pulmonary capillary wedge pressure, a direct physiological marker of HFpEF. Cohort B patients remain in scheduled long-term follow-up. The DMC's parallel review of Medera's randomized HFrEF Phase 2 study identified no safety concerns requiring changes to that study's conduct either.

Medera is now preparing for FDA discussions on the design of the next randomized stage, with the DMC's clean safety record across both dose cohorts providing the evidentiary foundation those interactions will require.

Source: Medera Inc. via GlobeNewswire, June 25, 2026.